Drug Profile
Pseudomonas vaccine - Provalis
Alternative Names: PsuedostatLatest Information Update: 16 May 2007
Price :
$50
*
At a glance
- Originator Provalis
- Developer Provalis; University of Newcastle, Australia
- Class Bacterial vaccines; Pseudomonas vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Bronchiectasis; Chronic bronchitis; Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections
Most Recent Events
- 17 Feb 2003 Suspended - Phase-I for Cystic fibrosis-associated respiratory tract infections in Australia (PO)
- 17 Feb 2003 Suspended - Preclinical for Pseudomonal infections in Australia (PO)
- 06 Sep 2002 This vaccine is still in active development